Prof Robert Orlowski gives an overview of the IMROZ study data. This study compared isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) to VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.

When combined with bortezomib, lenalidomide, and dexamethasone (VRd), isatuximab significantly improved progression-free survival and response rates versus VRd alone.

The EMA has approved isatuximab in combination with VRd for treating newly diagnosed multiple myeloma patients who cannot undergo transplant.

Historical data shows that non-transplant patients face worse outcomes, making this approval crucial.

The IMROZ study sets a new efficacy benchmark, indicating benefits for transplant ineligible NDMM patients, regardless of age or health status, with a manageable safety profile.

ecancer's filming has been kindly supported by Sanofi through the ecancer Global Foundation.

The content of this video is based on the SARCLISA^® EU Summary of Product Characteristics which can be accessed by clicking the link below:

https://www.ema.europa.eu/en/documents/product-information/sarclisa-epar-product-information_en.pdf

Sanofi does not recommend the use of its products in any manner inconsistent with that described in the label available in your country. Please refer to your local product labelling information before prescribing; view your country-specific product labelling information here. If this link does not directly go to your country-specific product labelling information, it can be accessed from the bottom of the screen here.

MAT-GLB-2500222-V1.0-02/2025